000829452 001__ 829452
000829452 005__ 20210129230304.0
000829452 0247_ $$2doi$$a10.1038/nrneurol.2017.44
000829452 0247_ $$2ISSN$$a1745-834X
000829452 0247_ $$2ISSN$$a1745-8358
000829452 0247_ $$2ISSN$$a1759-4758
000829452 0247_ $$2ISSN$$a1759-4766
000829452 0247_ $$2WOS$$aWOS:000400369800004
000829452 0247_ $$2altmetric$$aaltmetric:18584935
000829452 0247_ $$2pmid$$apmid:28387340
000829452 037__ $$aFZJ-2017-03151
000829452 082__ $$a610
000829452 1001_ $$0P:(DE-Juel1)131777$$aLangen, Karl-Josef$$b0$$eCorresponding author$$ufzj
000829452 245__ $$aAdvances in neuro-oncology imaging
000829452 260__ $$aNew York, NY$$bNature Publ. Group$$c2017
000829452 3367_ $$2DRIVER$$aarticle
000829452 3367_ $$2DataCite$$aOutput Types/Journal article
000829452 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1494509974_10087
000829452 3367_ $$2BibTeX$$aARTICLE
000829452 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000829452 3367_ $$00$$2EndNote$$aJournal Article
000829452 520__ $$aDespite the fact that MRI has evolved to become the standard method for diagnosis and monitoring of patients with brain tumours, conventional MRI sequences have two key limitations: the inability to show the full extent of the tumour and the inability to differentiate neoplastic tissue from nonspecific, treatment-related changes after surgery, radiotherapy, chemotherapy or immunotherapy. In the past decade, PET involving the use of radiolabelled amino acids has developed into an important diagnostic tool to overcome some of the shortcomings of conventional MRI. The Response Assessment in Neuro-Oncology working group — an international effort to develop new standardized response criteria for clinical trials in brain tumours — has recommended the additional use of amino acid PET imaging for brain tumour management. Concurrently, a number of advanced MRI techniques such as magnetic resonance spectroscopic imaging and perfusion weighted imaging are under clinical evaluation to target the same diagnostic problems. This Review summarizes the clinical role of amino acid PET in relation to advanced MRI techniques for differential diagnosis of brain tumours; delineation of tumour extent for treatment planning and biopsy guidance; post-treatment differentiation between tumour progression or recurrence versus treatment-related changes; and monitoring response to therapy. An outlook for future developments in PET and MRI techniques is also presented.
000829452 536__ $$0G:(DE-HGF)POF3-573$$a573 - Neuroimaging (POF3-573)$$cPOF3-573$$fPOF III$$x0
000829452 588__ $$aDataset connected to CrossRef
000829452 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, Norbert$$b1$$ufzj
000829452 7001_ $$0P:(DE-HGF)0$$aHattingen, Elke$$b2
000829452 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b3$$ufzj
000829452 773__ $$0PERI:(DE-600)2491518-X$$a10.1038/nrneurol.2017.44$$n5$$p279-289$$tNature reviews / Neurology$$v13$$x1759-4766$$y2017
000829452 8564_ $$uhttps://juser.fz-juelich.de/record/829452/files/nrneurol.2017.44.pdf$$yRestricted
000829452 8564_ $$uhttps://juser.fz-juelich.de/record/829452/files/nrneurol.2017.44.gif?subformat=icon$$xicon$$yRestricted
000829452 8564_ $$uhttps://juser.fz-juelich.de/record/829452/files/nrneurol.2017.44.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000829452 8564_ $$uhttps://juser.fz-juelich.de/record/829452/files/nrneurol.2017.44.jpg?subformat=icon-180$$xicon-180$$yRestricted
000829452 8564_ $$uhttps://juser.fz-juelich.de/record/829452/files/nrneurol.2017.44.jpg?subformat=icon-640$$xicon-640$$yRestricted
000829452 8564_ $$uhttps://juser.fz-juelich.de/record/829452/files/nrneurol.2017.44.pdf?subformat=pdfa$$xpdfa$$yRestricted
000829452 909CO $$ooai:juser.fz-juelich.de:829452$$pVDB
000829452 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b0$$kFZJ
000829452 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b1$$kFZJ
000829452 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b3$$kFZJ
000829452 9131_ $$0G:(DE-HGF)POF3-573$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$vNeuroimaging$$x0
000829452 9141_ $$y2017
000829452 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000829452 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000829452 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000829452 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000829452 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000829452 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000829452 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNAT REV NEUROL : 2015
000829452 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000829452 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000829452 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000829452 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000829452 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000829452 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNAT REV NEUROL : 2015
000829452 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000829452 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000829452 9201_ $$0I:(DE-82)080010_20140620$$kJARA-BRAIN$$lJARA-BRAIN$$x2
000829452 980__ $$ajournal
000829452 980__ $$aVDB
000829452 980__ $$aI:(DE-Juel1)INM-3-20090406
000829452 980__ $$aI:(DE-Juel1)INM-4-20090406
000829452 980__ $$aI:(DE-82)080010_20140620
000829452 980__ $$aUNRESTRICTED